文献速递功能神经外科

无切口经颅磁共振引导聚焦超声功能神经外科的安全性与靶向准确性:单中心180次治疗253个靶点的经验

Safety and accuracy of incisionless transcranial MR-guided focused ultrasound functional neurosurgery: single-center experience with 253 targets in 180 treatments.
PubMed 文献 · J Neurosurg · 2018-05-25

该单中心研究前瞻性评估了180次无切口经颅磁共振引导聚焦超声(MRgFUS)治疗慢性难治性特发性帕金森病、特发性震颤、小脑性震颤和神经病理性疼痛的副作用与靶向准确性。结果显示平均三维准确性为0.73±0.39 mm,共记录14起副作用事件,无出血,作者认为该技术靶向准确性较高且副作用较少。

要点

  • 180次治疗253个靶点,平均三维靶向准确性为0.73±0.39 mm。
  • 共记录14起副作用事件,无出血发生。
  • MoCA评分术后2天轻度改善(p=0.002),1年随访保持稳定(p=0.03)。

核心结论

  • 无切口经颅MRgFUS技术显示出比需要脑穿透的技术更高的靶向准确性和更低的副作用特征。
  • 在无穿透性脑移位的情况下,该技术避免将热损伤置于所选靶点之外,从而无需可逆性治疗能量应用。
  • 使用基于病理生理学的恰当靶点,可在保留感觉、运动及旁边缘/多模态丘脑皮质功能的同时获得确定性治疗效果。
  • 临床疗效未在本研究中分析,最终取决于恰当的靶点选择和靶点热损伤覆盖的优化。

研究设计与样本

  • 单中心前瞻性评估180次连续MRgFUS治疗慢性难治性特发性帕金森病、特发性震颤、小脑性震颤和神经病理性疼痛的副作用与靶向准确性。
  • 所有病例除1例(0.6%)外,术后至少监测3个月;该例术后早期病程平稳但失访。
  • 手术靶点包括苍白球丘脑束(苍白球丘脑束切断术,n=105)、小脑丘脑束(小脑丘脑束切断术,n=50)、中央外侧核(中央外侧丘脑切断术,n=84)、中央中核(中央中核丘脑切断术,n=12)和苍白球(苍白球切断术,n=2)。
  • 认知测试在术前、术后1-2天和术后1年进行;前29例使用简易精神状态检查(MMSE),之后改用蒙特利尔认知评估(MoCA)。
  • 在术后2天MR图像上对每个靶点进行病灶重建和靶向准确性测量;253个病灶中234个可进行三维重建。

主要发现

  • 平均MoCA评分术后2天轻度改善(p=0.002),1年随访保持稳定(p=0.03)。
  • 平均MMSE评分术后2天和1年随访也轻度改善,但改善无统计学显著性(分别为p=0.06和p=0.2)。
  • 平均(±标准差)准确性在内外侧、前后和背腹维度分别为0.32±0.29 mm、0.29±0.28 mm和0.44±0.39 mm;平均三维准确性为0.73±0.39 mm。
  • 180次治疗中共记录14起副作用事件,分为操作相关(n=4,2.2%)、对邻近结构的影响(n=3,1.7%)和疾病相关(n=7,3.9%);无出血发生。

局限性

  • 所有病例除1例(0.6%)外术后至少监测3个月;该例术后早期病程平稳但失访。
  • 临床疗效未在本研究中分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Since the first clinical application of the incisionless magnetic resonance-guided focused ultrasound (MRgFUS) technology only small series of patients have been reported, and thus only extrapolations of the procedure-related risks could be offered. In this study, the authors analyze side-effects and targeting accuracy in 180 consecutive treatments with MRgFUS for chronic therapy-resistant idiopathic Parkinson's disease (PD), essential tremor (ET), cerebellar tremor (CT), and neuropathic pain (NP), all performed in their dedicated center. METHODS: A total of 180 treatments with MRgFUS for chronic therapy-resistant idiopathic PD, ET, CT, and NP were prospectively assessed for side-effects and targeting accuracy. Monitoring for later side-effects was continued for at least 3 months after the procedure in all but 1 case (0.6%); in that single case, the patient was lost to follow-up after an uneventful early postoperative course. The surgical targets were the pallidothalamic tract (pallidothalamic tractotomy, n = 105), the cerebellothalamic tract (cerebellothalamic tractotomy, n = 50), the central lateral nucleus (central lateral thalamotomy, n = 84), the centrum medianum (centrum medianum thalamotomy, n = 12), and the globus pallidus (pallidotomy, n = 2). Cognitive testing was performed before, 1-2 days after, and 1 year after the procedure. The Mini-Mental State Examination (MMSE) was used for the first 29 cases and was then replaced by the Montreal Cognitive Assessment (MoCA). Lesion reconstruction and measurement of targeting accuracy were done on 2-day posttreatment MR images for each performed target. To determine targeting accuracy measurement, 234 out of the 253 lesions depicted in the 2-day postoperative MR examination could be 3D-reconstructed. RESULTS: The mean MoCA score was slightly improved 2 days postoperatively (p = 0.002) and remained stable at 1-year follow-up (p = 0.03). The mean MMSE score was also slightly improved 2 days postoperatively and at 1-year follow-up, but the improvement was not statistically significant (p = 0.06 and p = 0.2, respectively). The mean (± SD) accuracy was 0.32 ± 0.29 mm, 0.29 ± 0.28 mm, and 0.44 ± 0.39 mm for the mediolateral, anteroposterior, and dorsoventral dimensions, respectively. The mean 3D accuracy was 0.73 ± 0.39 mm. As to side-effects, 14 events over 180 treatments were documented. They were classified into procedure-related (n = 4, 2.2%), effect on neighboring structures (n = 3, 1.7%), and disease-related (n = 7, 3.9%). There was no bleeding. CONCLUSIONS: The incisionless transcranial MRgFUS technology demonstrates a higher targeting accuracy and a lower side-effect profile than techniques requiring cerebral penetration. In the absence of penetration brain shift, this technique avoids the placement of a thermolesion away from the chosen target, thus suppressing the need for reversible therapeutic energy application. With the use of proper physiopathology-based targets, definitive therapeutic effects can be coupled with sparing of sensory, motor, and paralimbic/multimodal thalamocortical functions. Clinical efficacy, not analyzed in this investigation, will ultimately rest in proper target selection and optimized thermolesional coverage of the target.

来源:J Neurosurg,查看原文。版权归原作者所有。

引用

  1. Gallay MN, Moser D, Jeanmonod D, et al. Safety and accuracy of incisionless transcranial MR-guided focused ultrasound functional neurosurgery: single-center experience with 253 targets in 180 treatments. J Neurosurg. 2018. PMID: 29799340. doi:10.3171/2017.12.JNS172054

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。